These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33593740)

  • 1. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    De Santis M; Voza A; Savevski V; Badalamenti S; Cecconi M; Mantovani A; Selmi C
    Ann Rheum Dis; 2023 May; 82(5):e111. PubMed ID: 33593740
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Kaklamanos A; Karamichalos P; Vlachoyiannopoulos PG; Tzioufas AG
    Ann Rheum Dis; 2023 Jun; 82(6):e134. PubMed ID: 33903096
    [No Abstract]   [Full Text] [Related]  

  • 3. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Charles P
    Ann Rheum Dis; 2023 May; 82(5):e108. PubMed ID: 33589440
    [No Abstract]   [Full Text] [Related]  

  • 4. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Calvo-Aranda E; Cañamares-Orbis I; Novella-Navarro M; Martinez-Alcala A; Ortega de la O MDC; Escobar-Rodriguez I; Sanchez-Aranda FM
    Ann Rheum Dis; 2023 Feb; 82(2):e34. PubMed ID: 33318061
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Smolen JS
    Ann Rheum Dis; 2023 May; 82(5):e110. PubMed ID: 33658235
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles.
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e109. PubMed ID: 33589439
    [No Abstract]   [Full Text] [Related]  

  • 7. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
    Klopfenstein T; Gendrin V; Conrozier T; Gerazime A; Puyraveau M; Zayet S
    Ann Rheum Dis; 2023 Jul; 82(7):e153. PubMed ID: 34162593
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 Jun; 82(6):e135. PubMed ID: 33903095
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by De Santis
    Ramiro S; Mostard RLM; Landewé RBM
    Ann Rheum Dis; 2023 May; 82(5):e112. PubMed ID: 33593737
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda
    Ramiro S; Mostard R; Landewé RB
    Ann Rheum Dis; 2023 Feb; 82(2):e35. PubMed ID: 33318060
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study'' by Klopfenstein
    Landewé RB; Ramiro S; Mostard RLM
    Ann Rheum Dis; 2023 Jul; 82(7):e154. PubMed ID: 34162596
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.
    Landewé RBM; Ramiro S; Mostard RLM
    RMD Open; 2021 Mar; 7(1):. PubMed ID: 33790049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
    Suresh K; Figart M; Formeck S; Mehmood T; Abdel Salam M; Bassilly D
    J Investig Med High Impact Case Rep; 2021; 9():23247096211019557. PubMed ID: 34105382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging nanomaterials applied for tackling the COVID-19 cytokine storm.
    Yang X; You J; Wei Y; Li H; Gao L; Guo Q; Huang Y; Gong C; Yi C
    J Mater Chem B; 2021 Oct; 9(39):8185-8201. PubMed ID: 34528037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination.
    Ramatillah DL; Gan SH; Pratiwy I; Syed Sulaiman SA; Jaber AAS; Jusnita N; Lukas S; Abu Bakar U
    PLoS One; 2022; 17(1):e0262438. PubMed ID: 35077495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series.
    Basnet A; Shrestha MR; Thapa R; Tamang B; Shrestha A; Rawal P; Duwal Shrestha SK; Karki L; Rai SK
    JNMA J Nepal Med Assoc; 2022 Aug; 60(252):727-731. PubMed ID: 36705224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
    Baker EH; Patel K; Ball J; Edwards S; Harrison TS; Kaul A; Koh M; Krishna S; Leaver S; Kumar V; Forton DM
    Br J Clin Pharmacol; 2021 Mar; 87(3):1584-1586. PubMed ID: 32656822
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
    Dravid A; Kashiva R; Khan Z; Memon D; Kodre A; Potdar P; Mane M; Borse R; Pawar V; Patil D; Banerjee D; Bhoite K; Pharande R; Kalyani S; Raut P; Bapte M; Mehta A; Reddy MS; Bhayani K; Laxmi SS; Vishnu PD; Srivastava S; Khandelwal S; More S; Shinde R; Pawar M; Harshe A; Kadam S; Mahajan U; Joshi G; Mane D
    Medicine (Baltimore); 2021 Jul; 100(29):e26705. PubMed ID: 34398044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.